LAMC2 acts as a novel therapeutic target of cetuximab in laryngeal cancer

This study was set out to determine the function of LAMC2 in laryngeal cancer (LC). Initially, we identified the expression of LAMC2 in LC cells and tissues using TCGA datasets, GEO datasets (GSE143224), qRT-PCR, and western blot. Besides, we analyzed the correlations between LAMC2 and clinicopathologic features in LC patients. The CCK-8 assays were performed to detect cell viability and the half-maximal inhibitory concentration of cetuximab (IC50) in LC cells. We explored the correlations between LAMC2 and EGFR and further explored the regulation mechanism of cetuximab in LC. This study identified a high expression of LAMC2 in LC cells and tissues. The expression levels of LAMC2 were associated with TNM classification, lymph node (LN) metastasis, differentiation, and overall survival (OS). LAMC2 significantly promoted cell proliferation and cell viability. Besides, cetuximab significantly inhibited LAMC2 expression levels. LAMC2 significantly reversed the effect of cetuximab suppressing cell proliferation in LC cells. In conclusion, LAMC2 may act as a novel anti-cancer target in LC.

Automated summary

This study revealed the high expression of LAMC2 in laryngeal cancer cells and tissues, which was associated with clinicopathologic features and survival rate. LAMC2 promoted cell proliferation and viability, while cetuximab inhibited LAMC2 levels and its effect on cell proliferation was reversed by LAMC2. This suggests that LAMC2 could serve as a novel anti-cancer target in laryngeal cancer.